Xiaobo Yang

Dr. Xiaobo Yang

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MWMoli Wu
Moli Wu
DSDanyang Song
Danyang Song
HLHui Li
Hui Li
NANisar Ahmad
Nisar Ahmad
HXHong Xu
Hong Xu
XSXiaohong Shu
Xiaohong Shu
Chemoresistance blunts the efficacy of temozolomide (TMZ) in the treatment of glioblastoma (GBM). Elevated levels of O6-methylguanine-DNA methyltransferase (MGMT) and activation of signal transducer and of transcription 3 (STAT3) have been reported to correlate with GBM resistance to alkylator chemotherapy. Resveratrol (Res) inhibits tumor growth and improves drug chemosensitivity by targeting STAT3 signaling. Whether the combined therapy of TMZ and Res could enhance chemosensitivity against GBM cells and the underlying molecular mechanism remains to be determined. In this study, Res was found to effectively improve chemosensitivities of different GBM cells to TMZ, which was evaluated by CCK-8, flow cytometry, and cell migration assay. The combined use of Res and TMZ downregulated STAT3 activity and STAT3-regulated gene products, thus inhibited cell proliferation and migration, as well as induced apoptosis, accompanied by increased levels of its negative regulators: PIAS3, SHP1, SHP2, and SOCS3. More importantly, a combination therapy of Res and TMZ reversed TMZ resistance of LN428 cells, which could be related to decreased MGMT and STAT3 levels. Furthermore, the JAK2-specific inhibitor AG490 was used to demonstrate that a reduced MGMT level was mediated by STAT3 inactivation. Taken together, Res inhibited STAT3 signaling through modulation of PIAS3, SHP1, SHP2, and SOCS3, thereby attenuating tumor growth and increasing sensitivity to TMZ. Therefore, Res is an ideal candidate to be used in TMZ combined chemotherapy for GBM.

20 September 2024 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
XLXin Li
Xin Li
LGLiyang Guan
Liyang Guan
ZLZhi'EN Liu
Zhi'EN Liu
ZDZaixing Du
Zaixing Du
QYQianhui Yuan
Qianhui Yuan
LLLi Lu
Li Lu

21 September 2022 in Drug Delivery
Verified
Journal Article
Open access
YWYinan Wang
Yinan Wang
YSYanan Su
Yanan Su
YYYunqiao Yang
Yunqiao Yang
HJHuan Jin
Huan Jin
MWMoli Wu
Moli Wu
XSXiaohong Shu
Xiaohong Shu
Effective chemotherapy for clinical treatment of brain diseases is still lacking due to the poor penetration of the blood-brain barrier (BBB). The aim of this study was to construct a folate modified pterostilbene (Pt) loaded polymeric micellar delivery system (F-Pt/M) with mPEG-PCL as carrier material to aim at penetrating the BBB for brain tissue targeting via receptor-mediated endocytosis. In this study, F-Pt/M was prepared using thin-film hydration method and then optimized by response surface methodology (RSM) with the entrapment efficiency (EE), drug loading (DL) and hydrodynamic diameter (HD) as indexes. The average hydrodynamic diameter and zeta potential of optimal F-Pt/M were 133.2 nm and 24.6 mV, respectively. DL (18.3%) and EE (98.6%) made the solubility of Pt in water about 25 times higher than that of crude Pt. Results of DSC evaluation revealed that drugs were successfully encapsulated inside the polymeric micelles. TEM images showed that homogeneous spherical micellar structures with a narrow size distribution were developed. The release result in vitro showed that F-Pt/M presented sustained release behavior compared to control free Pt solution. Compared to non-targeted Pt/M, F-Pt/M had a significantly higher cytotoxicity against FR-overexpressing A172 cells. In vitro cellular uptake tests illustrated that the micellar delivery system could significantly improve the accumulation of drugs in target cells via receptor-mediated endocytosis. BBB penetration value (P) of F-Pt/M was about 4 folds higher than that of free Pt group. In addition, drug targeting index (DTI) was calculated to determine targeting of F-Pt/M to the brain which was found to be 4.89, implying improved brain targeting was achieved. Hence, the developed F-Pt/M exhibited great potential for delivering more drug molecules across the BBB for the treatment of brain diseases. Graphical Abstract A novel folate modified pterostilbene (Pt)-loaded polymeric micelle (F-Pt/M) drug delivery system, composing of Pt (as model drug), folate (as targeting ligand) and PEG2000/PEG3400-PCL2000 (as self-assembled material), was prepared by thin-film hydration method. The developed F-Pt/M enhanced the penetration of Pt across the blood-brain barrier via receptor-mediated endocytosis. It might have the potential to be developed as an attractive micellar system for effective chemotherapy against some brain diseases.

1 April 2013 in Journal of Molecular Catalysis B: Enzymatic
Verified
Journal Article
Closed access
XYXiaobo Yang
Xiaobo Yang
JHJie Hou
Jie Hou
DLDan Liu
Dan Liu
SDSa Deng
Sa Deng
ZWZhi Bin Wang
Zhi Bin Wang
XMXiao Chi Ma
Xiao Chi Ma

1 November 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YJYongming Jia
Yongming Jia
Zhihao LiuZhihao Liu
Zhihao Liu
XHXiaokui Huo
Xiaokui Huo
CWChangyuan Wang
Changyuan Wang
QMQiang Meng
Qiang Meng
KLKexin Liu
Kexin Liu

16 August 2024 in Neurotherapeutics
Verified
Journal Article
Open access
NANisar Ahmad
Nisar Ahmad
LCLixue Chen
Lixue Chen
ZYZixi Yuan
Zixi Yuan
XMXiaodong Ma
Xiaodong Ma
XYXiaobo Yang
Xiaobo Yang
XSXiaohong Shu
Xiaohong Shu
Glioblastoma (GBM) is a brain tumor characterized by its aggressive and invasive properties. It is found that STAT3 is abnormally activated in GBM, and inhibiting STAT3 signaling can effectively suppress tumor progression. In this study, novel pyrimidine compounds, BY4003 and BY4008, were synthesized to target the JAK3/STAT3 signaling pathway, and their therapeutic efficacy and mechanisms of action were evaluated and compared with Tofacitinib in U251, A172, LN428 and patient-derived glioblastoma cells. The ADP-Glo™ kinase assay was utilized to assessed the inhibitory effects of BY4003 and BY4008 on JAK3, a crucial member of the JAK family. The results showed that both compounds significantly inhibited JAK3 enzyme activity, with IC50 values in the nanomolar range. The antiproliferative effects of BY4003, BY4008, and Tofacitinib on GBM and patient-derived glioblastoma cells were evaluated by MTT and H&E assays. The impact of BY4003 and BY4008 on GBM cell migration and apoptosis induction was assessed through wound healing, transwell, and TUNEL assays. STAT3-regulated protein expression and relative mRNA levels were analyzed by western blotting, immunocytochemistry, immunofluorescence, and qRT-PCR. It was found that BY4003, BY4008 and Tofacitinib could inhibit U251, A172, LN428 and patient-derived glioblastoma cells growth and proliferation. Results showed decreased expression of STAT3-associated proteins, including p-STAT3, CyclinD1, and Bcl-2, and increased expression of Bax, a pro-apoptotic protein, as well as significant down-regulation of STAT3 and STAT3-related genes. These findings suggested that BY4003 and BY4008 could inhibit GBM growth by suppressing the JAK3/STAT3 signaling pathway, providing valuable insights into the therapeutic development of GBM.